
Glioma - Pipeline Insight, 2022
Description
Glioma - Pipeline Insight, 2022
DelveInsight’s, “Glioma - Pipeline Insight, 2022,” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Glioma: Overview
Glioma is the most common form of central nervous system (CNS) neoplasm that originates from glial cells. In the United States, there are six cases of gliomas diagnosed per 100,000 people every year. Gliomas are very diffusely infiltrative tumors that affect the surrounding brain tissue. Glioblastoma is the most malignant type while pilocytic astrocytomas are the least malignant brain tumors. In the past, these diffuse gliomas were classified into different subtypes and grades based on histopathologies such as a diffuse astrocytoma, oligodendrogliomas, or mixed gliomas/oligoastrocytomas. Recently, gliomas were classified based on molecular and genetic markers. These advances have more specific prognostic and therapeutic benefits for patients with gliomas. In addition to molecular and genetic markers, gliomas are classified in grade I to IV based on the degree of proliferation indicated by the mitotic index and the presence or absence of necrosis. There are three common types of gliomas, which are classified based on the phenotypic cell characteristics: astrocytomas, ependymomas, and oligodendrogliomas. These cell gliomas are further classified to low grade, atypical, and high-grade tumors based on cell morphology, mitotic activities, and molecular marker. The World Health Organization (WHO) grading system utilizes molecular markers that have shown to have significant prognostic and therapeutic implications. There is an estimation of 80,000 newly diagnosed cases of primary brain tumor each year in the United States. Around one-fourth of which (i.e. 20,000) are gliomas. The total number of glioblastomas diagnosed each year is around 12,000 cases (approximately 15% of total newly diagnosed brain tumors). Gliomas in general, specifically glioblastomas, are very difficult to treat. Despite advances in understanding the molecular biology and genetics of gliomas, no significant impact has been made toward preventing the lethality of high-grade gliomas. Therefore, there is a continuing need for clinical and basic science investigations to advance the care of this lethal disease.
""Glioma - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Glioma pipeline landscape is provided which includes the disease overview and Glioma treatment guidelines. The assessment part of the report embraces, in depth Glioma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Glioma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glioma Emerging Drugs
Further product details are provided in the report……..
Glioma: Therapeutic Assessment
This segment of the report provides insights about the different Glioma drugs segregated based on following parameters that define the scope of the report, such as:
Glioma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Glioma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glioma drugs.
Glioma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Glioma - Pipeline Insight, 2022,” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Glioma: Overview
Glioma is the most common form of central nervous system (CNS) neoplasm that originates from glial cells. In the United States, there are six cases of gliomas diagnosed per 100,000 people every year. Gliomas are very diffusely infiltrative tumors that affect the surrounding brain tissue. Glioblastoma is the most malignant type while pilocytic astrocytomas are the least malignant brain tumors. In the past, these diffuse gliomas were classified into different subtypes and grades based on histopathologies such as a diffuse astrocytoma, oligodendrogliomas, or mixed gliomas/oligoastrocytomas. Recently, gliomas were classified based on molecular and genetic markers. These advances have more specific prognostic and therapeutic benefits for patients with gliomas. In addition to molecular and genetic markers, gliomas are classified in grade I to IV based on the degree of proliferation indicated by the mitotic index and the presence or absence of necrosis. There are three common types of gliomas, which are classified based on the phenotypic cell characteristics: astrocytomas, ependymomas, and oligodendrogliomas. These cell gliomas are further classified to low grade, atypical, and high-grade tumors based on cell morphology, mitotic activities, and molecular marker. The World Health Organization (WHO) grading system utilizes molecular markers that have shown to have significant prognostic and therapeutic implications. There is an estimation of 80,000 newly diagnosed cases of primary brain tumor each year in the United States. Around one-fourth of which (i.e. 20,000) are gliomas. The total number of glioblastomas diagnosed each year is around 12,000 cases (approximately 15% of total newly diagnosed brain tumors). Gliomas in general, specifically glioblastomas, are very difficult to treat. Despite advances in understanding the molecular biology and genetics of gliomas, no significant impact has been made toward preventing the lethality of high-grade gliomas. Therefore, there is a continuing need for clinical and basic science investigations to advance the care of this lethal disease.
""Glioma - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Glioma pipeline landscape is provided which includes the disease overview and Glioma treatment guidelines. The assessment part of the report embraces, in depth Glioma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Glioma.
- In the coming years, the Glioma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence Glioma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the Glioma treatment market. Several potential therapies for Glioma are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Glioma market size in the coming years.
- Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Glioma) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
This segment of the Glioma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Glioma Emerging Drugs
- ONC 201: Chimerix
- DSP-7888: Sumitomo Dainippon Pharma
- AV-GBM-1: AIVITA Biomedical
- DB102: Denovo Biopharma
- AB-218: AnHeart Therapeutics
Further product details are provided in the report……..
Glioma: Therapeutic Assessment
This segment of the report provides insights about the different Glioma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Glioma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
- Molecule Type
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
- Product Type
Glioma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Glioma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Glioma drugs.
Glioma Report Insights
- Glioma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Glioma drugs?
- How many Glioma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Glioma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Glioma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Glioma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Chimerix
- Sumitomo Dainippon Pharma
- AIVITA Biomedical
- Denovo Biopharma
- Plus Therapeutics
- Philogen S.p.A.
- Xennials Therapeutics
- Laminar Pharmaceuticals
- Shanghai Gencells Therapeutics
- AnHeart Therapeutics Inc.
- Istari Oncology, Inc.
- Beijing Pearl Biotechnology Limited Liability Company
- Epitopoietic Research Corporation
- Everfront Biotech Co., Ltd.
- CNS Pharmaceuticals
- Bexion Pharmaceuticals, Inc.
- Lee's Pharmaceutical Limited
- Merck & Co
- Oblato, Inc.
- OncoSynergy, Inc.
- SystImmune
- Aadi Bioscience, Inc.
- Day One Biopharmaceuticals
- SpringWorks Therapeutics, Inc.
- Bristol-Myers Squibb
- PTC Therapeutics
- Apices Soluciones S.L.
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- TCRCure Biopharma
- SonALAsense, Inc.
- Midatech Pharma US Inc.
- Prelude Therapeutics
- Incyte Corporation
- BioMimetix JV, LLC
- GlaxoSmithKline
- DNAtrix
- Oblato, Inc.
- NeoImmuneTech
- Nuvation Bio Inc.
- Forma Therapeutics
- NanoPharmaceuticals LLC
- Erimos Pharmaceuticals
- Alaunos Therapeutics
- Symphogen
- Samus Therapeutics, Inc.
- Istari Oncology
- Neonc Technologies, Inc.
- Agios Pharmaceuticals
- Basilea Pharmaceutica
- BeiGene
- Kazia Therapeutics
- AstraZeneca
- Nerviano Medical Sciences
- VBL Therapeutics
- ONC 201
- DSP-7888
- AV-GBM-1
- DB102
- BGB-290
- BAL101553
- Rhenium Nanoliposomes
- GDC-0084
- D2C7-IT
- Perillyl alcohol
- NMS-03305293
- Selumetinib
- Terameprocol
- Icapamespib
- Sym004
- Niraparib
- ivosidenib
- Ad-RTS-hIL-12
- BMX-001
- DNX-2401
- fb-PMT
- FT-2102
- OKN-007
- NUV-422
- rhIL-7-hyFc
- Anlotinib hydrochloride
- Histone H3.3-K27M
- Epacadostat
- PRT811
- AloCELYVIR
- MTX110
- SONALA-001
- PTC596
- Nivolumab
- L19TNF
- NTX-301
- Mirdametinib
- 2-OHOA
- Tumor Infiltrating Lymphocytes
- AB-218
- PVSRIPO
- PLB1001
- ERC1671
- Cerebraca wafer
- Berubicin Hydrochloride
- BXQ-350
- TG02
- Pembrolizumab
- OKN-007
- OS2966
- GNC-039
- ABI-009
- DAY101
- VB 111
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
300 Pages
- Introduction
- Executive Summary
- Glioma: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Glioma – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- VB 111: VBL Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- ONC 201: Chimerix
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Autologous tumour infiltrating lymphocytes: Shanghai Gencells Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Autologous T-cell therapy: Kairos Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Glioma Key Companies
- Glioma Key Products
- Glioma- Unmet Needs
- Glioma- Market Drivers and Barriers
- Glioma- Future Perspectives and Conclusion
- Glioma Analyst Views
- Glioma Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.